Article
Long-term persistence of HCV resistance-associated substitutions after DAA treatment failure.
Journal of hepatology - 1 Jan 2023
Dietz Julia, Müllhaupt Beat, Buggisch Peter, Graf Christiana, Peiffer Kai-Henrik, Matschenz Katrin, Schattenberg Jörn M, Antoni Christoph, Mauss Stefan, Niederau Claus, Discher Thomas, Trauth Janina, Dultz Georg, Schulze Zur Wiesch Julian, Piecha Felix, Klinker Hartwig, Müller Tobias, Berg Thomas, Neumann-Haefelin Christoph, Berg Christoph P, Zeuzem Stefan, Sarrazin Christoph
Abstract excerpt
BACKGROUND & AIMS: Data on the long-term persistence of HCV resistance-associated substitutions (RASs) after treatment with direct-acting antivirals (DAAs) are limited. This study evaluated the persistence of NS3, NS5A, and NS5B RASs for up to 5 years after the end of treatment (EOT). METHODS: We included samples from 678 individuals with an HCV genotype (GT) 1 or 3 infection and virologic DAA treatment failure...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
